WEBINAR

Using Pharmacogenetic Markers in Clinical Treatment

The Pros and Cons of Preemptive Genetic Testing



Wednesday, November 6, 2013

12 noon Eastern, 9 a.m. Pacific, 5 p.m. UK, 6 p.m. Central Europe

Genetic variations in genes that metabolize and transport drugs in the body are known to affect the therapeutic response in different individuals by altering the absorption, distribution, metabolism, or elimination (ADME) of those drugs. Preemptively assessing multiple pharmacogenetic factors holds tremendous potential to improve treatment by understanding the effect of important genetic variants in advance, rather than waiting to test a patient for these markers for each individual drug at the time of prescription. Higher throughput and more comprehensive clinical genetic testing is now available, allowing clinical testing to expand from a single gene to comprehensive panels of relevant genes—a more attractive and cost-effective approach. Preemptive clinical testing for pharmacogenetic genes has been implemented in a pediatric setting. This approach has great advantages for both the patient and the physician. However, careful consideration with regard to medical data management and communication with patients and health care providers is necessary.

During this webinar, the speaker will:

- Summarize recent progress and the current status of pharmacogenetic testing in the clinic
- Describe how to select the most appropriate genetic testing platforms
- Provide insight into implementation in clinical practice
- Answer your questions live during the event!

Speaker

Ulrich Broeckel, M.D.
Medical College of Wisconsin
Milwaukee, WI

REGISTER NOW!
webinar.sciencemag.org

Webinar sponsored by

affymetrix
Biology for a better world

Brought to you by the *Science*/AAAS Custom Publishing Office

Science
AAAS